Skip to content

Dyslipidemia-related Risk Factors in Dialysis

Dyslipidemia-related Variables as Risk Factor for Cardiovascular Disease in Patients on the End-stage of Renal Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02072837
Enrollment
96
Registered
2014-02-27
Start date
2012-01-31
Completion date
2014-01-31
Last updated
2014-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Chronic Renal Disease, Dyslipidemia

Keywords

hemodialysis, dyslipidemia, cardiovascular disease

Brief summary

In this study, we studied lipoprotein abnormalities-related variables as risk factors for the development of cardiovascular disease in patients on renal replacement therapies.We studied 96 dialyzed patients, 62 males and 34 females, on mean age 62.1 years old and 24 healthy controls.We concluded that metabolic acidosis activating the inflammation and lipoprotein oxidation influences the dyslipidemia and cardiovascular morbidity of patients on renal replacement therapies.Dialysis adequacy was positively associated to cardioprotective HDL.Peritoneal dialysis holds a better acidosis level and lower oxidized lipids than hemodialysis modalities.

Detailed description

Blood samples were obtained by venipuncture in the peritoneal dialyzed patients and control group in a twelve hours fasting state.In hemodialyzed patients blood was drawn just before the start of the mean weekly dialysis session also in a twelve hours fasting state from the vascular access. All samples were received once at baseline time ( in the start of the study ). Peripheral systolic and diastolic blood pressures were calculated as an average of 10 measurements during a renal replacement treatment month in the starting time of the study. Also, electrocardiographic examination, echocardiography and the calculation of ankle-brachial blood pressure index became once in the start of the study.

Interventions

None listed

Sponsors

National and Kapodistrian University of Athens
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
24 Years to 87 Years
Healthy volunteers
Yes

Inclusion criteria

* permanent renal replacement therapy more than 6 months and * accurate dry body weight

Exclusion criteria

* acute illness, * significant infection, * malignancy, * Kt/V for urea \<1.2.

Design outcomes

Primary

MeasureTime frame
Associations between dyslipidemia with cardiovascular disease on patients on renal replacement therapyFebruary 2014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026